Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,536.00
Bid: 12,534.00
Ask: 12,538.00
Change: 132.00 (1.06%)
Spread: 4.00 (0.032%)
Open: 12,500.00
High: 12,562.00
Low: 12,444.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A COVID-19 shot for $150? Online scams surge as slow vaccine rollout frustrates

Tue, 05th Jan 2021 12:00

By Tina Bellon

NEW YORK, Jan 5 (Reuters) - As millions of people await
their turn to get a COVID-19 vaccine that could be months away,
scammers online, in emails and on messaging apps are luring
victims with claims they can deliver shots within days for as
little as $150.

COVID-19 vaccine scams are on the rise, according to
European and U.S. government officials who are warning the
public of fraudsters out for money and personal data.

A Reuters search online, in dark web forums and on messaging
app Telegram found seven different offers for alleged COVID-19
vaccines.

Scams include emails promising entry to supposedly secret
lists for early vaccine access and robocallers impersonating
government agencies. Message boards on the so-called dark web
have added COVID-19 vaccines to more traditional illicit goods
for sale.

The U.S. FBI and Interpol, among others, have warned of
emerging pandemic-related fraud schemes, saying false cures and
vaccines advertised on fake websites could pose cyber threats
and a significant risk to peoples' health, or even lives.

Website domains containing the word vaccine in combination
with COVID-19 or coronavirus more than doubled since October to
roughly 2,500 in November, when the first legitimate vaccines
were nearing regulatory approval, according to cybersecurity
firm Recorded Future, which is tracking COVID-19 fraud online.

"So far a lot of these domains just appear to be
opportunistic registrations, but some are going to be used for
phishing attempts to have people click on (malicious) links,"
said Lindsay Kaye, director of operational outcomes at Recorded
Future.

Kaye said her team, which also scours the dark web, so far
has not come across any legitimate vaccine diverted from
healthcare facilities or national stockpiles.

The scams are preying on concerns about the far
slower-than-promised rollout of vaccines to protect against the
virus that has claimed more than 1.8 million lives worldwide so
far. Most people will likely have to wait well into the spring,
or even summer, to get their shot.

In the United States, only about 4.5 million people had
received their first shot as of Monday, the U.S. Centers for
Disease Control and Prevention reported. That is a fraction of
the 20 million who were supposed to have been vaccinated by the
end of 2020, according to earlier government forecasts.

VACCINES, GUNS AND MONEY

On dark web forum Agartha, fake COVID-19 vaccines were
offered next to cocaine, opioid medication, "super high quality
fake money," hand guns and gift cards. Posts showed stock photos
of vaccines and offered vials for $500 and $1,000, or the
equivalent in Bitcoin.

On another dark web site, a seller claiming to be from the
"Wuhan Institute of Science" offered COVID-19 vaccines in
exchange for a donation, and asked buyers to provide their
medical history.

On Telegram, several channels claimed to offer COVID-19
vaccines, accompanied by stock images. One user offered supposed
Moderna Inc vaccines for $180, and claimed the vaccine
from Pfizer Inc and BioNTech SE could be had
for $150 and AstraZeneca's for $110 per vial.

Asked how the vaccines would be shipped, the account creator
said they were transported in "regulated temperature packs" and
ice packs within a few days, or overnight for an additional
charge.

Actual COVID-19 vaccines, particularly the Pfizer/BioNTech
offering, must be temperature controlled to remain effective,
with drugmakers equipping shipments with temperature trackers to
ensure the cold chain. Vaccine shipments and distribution are
also tightly controlled by officials and will be administered
at no cost.

The United States has so far authorized two COVID-19
vaccines for emergency use - the ones from Pfizer/BioNTech and
Moderna. The European Union to date has authorized the
Pfizer/BioNTech vaccine and is expected to clear the Moderna
vaccine this week.

The UK has already authorized those two and just added the
vaccine developed by Oxford University with AstraZeneca.

Asked about vaccine scams, Pfizer said it had taken
meticulous steps to reduce the risk of counterfeiting and
tracked trends very carefully.

"Patients should never try to secure a vaccine online - no
legitimate vaccine is sold online - and only get vaccinated at
certified vaccination centers or by certified healthcare
providers," a Pfizer spokesman said in a statement.

Moderna referred a request for comment to the U.S.
Department of Health and Human Services (HHS), which did not
respond. AstraZeneca did not respond to a request for comment.

The HHS, FBI and U.S. Department of Justice have urged the
public to report any COVID-19 vaccine scams, including people
asking for out-of-pocket payments for the vaccine and online
vaccine advertisements.

(Reporting by Tina Bellon in New York
Editing by Bill Berkrot)

More News
Today 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
Today 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.